Matthew B Lanktree1,2, Elsa Guiard1, Pedram Akbari1, Marina Pourafkari3, Ioan-Andrei Iliuta1, Syed Ahmed1, Amirreza Haghighi1, Ning He1, Xuewen Song1, Andrew D Paterson4,5, Korosh Khalili3, York P C Pei6. 1. Division of Nephrology, University Health Network and University of Toronto, Toronto, Ontario, Canada. 2. Division of Nephrology, St. Joseph's Healthcare Hamilton and McMaster University, Hamilton, Ontario, Canada. 3. Department of Medical Imaging, University Health Network and University of Toronto, Toronto, Ontario, Canada. 4. Program in Genetics and Genome Biology, The Hospital for Sick Children, Ontario, Canada. 5. Division of Epidemiology and Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 6. Division of Nephrology, University Health Network and University of Toronto, Toronto, Ontario, Canada york.pei@uhn.ca.
Abstract
BACKGROUND AND OBJECTIVES: Progression of autosomal dominant polycystic kidney disease (ADPKD) is highly variable. On average, protein-truncating PKD1 mutations are associated with the most severe kidney disease among all mutation classes. Here, we report that patients with protein-truncating PKD1 mutations may also have mild kidney disease, a finding not previously well recognized. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From the extended Toronto Genetic Epidemiologic Study of Polycystic Kidney Disease, 487 patients had PKD1 and PKD2 sequencing and typical ADPKD imaging patterns by magnetic resonance imaging or computed tomography. Mayo Clinic Imaging Classification on the basis of age- and height-adjusted total kidney volume was used to assess their cystic disease severity; classes 1A or 1B were used as a proxy to define mild disease. Multivariable linear regression was performed to test the effects of age, sex, and mutation classes on log-transformed height-adjusted total kidney volume and eGFR. RESULTS: Among 174 study patients with typical imaging patterns and protein-truncating PKD1 mutations, 32 (18%) were found to have mild disease on the basis of imaging results (i.e., Mayo Clinic Imaging class 1A-1B), with their mutations spanning the entire gene. By multivariable analyses of age, sex, and mutation class, they displayed mild disease similar to patients with PKD2 mutations and Mayo Clinic Imaging class 1A-1B. Most of these mildly affected patients with protein-truncating PKD1 mutations reported a positive family history of ADPKD in preceding generations and displayed significant intrafamilial disease variability. CONCLUSIONS: Despite having the most severe mutation class, 18% of patients with protein-truncating PKD1 mutations had mild disease on the basis of clinical and imaging assessment. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_02_18_CJN11100720_final.mp3.
BACKGROUND AND OBJECTIVES: Progression of autosomal dominant polycystic kidney disease (ADPKD) is highly variable. On average, protein-truncating PKD1 mutations are associated with the most severe kidney disease among all mutation classes. Here, we report that patients with protein-truncating PKD1 mutations may also have mild kidney disease, a finding not previously well recognized. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From the extended Toronto Genetic Epidemiologic Study of Polycystic Kidney Disease, 487 patients had PKD1 and PKD2 sequencing and typical ADPKD imaging patterns by magnetic resonance imaging or computed tomography. Mayo Clinic Imaging Classification on the basis of age- and height-adjusted total kidney volume was used to assess their cystic disease severity; classes 1A or 1B were used as a proxy to define mild disease. Multivariable linear regression was performed to test the effects of age, sex, and mutation classes on log-transformed height-adjusted total kidney volume and eGFR. RESULTS: Among 174 study patients with typical imaging patterns and protein-truncating PKD1 mutations, 32 (18%) were found to have mild disease on the basis of imaging results (i.e., Mayo Clinic Imaging class 1A-1B), with their mutations spanning the entire gene. By multivariable analyses of age, sex, and mutation class, they displayed mild disease similar to patients with PKD2 mutations and Mayo Clinic Imaging class 1A-1B. Most of these mildly affected patients with protein-truncating PKD1 mutations reported a positive family history of ADPKD in preceding generations and displayed significant intrafamilial disease variability. CONCLUSIONS: Despite having the most severe mutation class, 18% of patients with protein-truncating PKD1 mutations had mild disease on the basis of clinical and imaging assessment. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2021_02_18_CJN11100720_final.mp3.
Authors: Emilie Cornec-Le Gall; Rory J Olson; Whitney Besse; Christina M Heyer; Vladimir G Gainullin; Jessica M Smith; Marie-Pierre Audrézet; Katharina Hopp; Binu Porath; Beili Shi; Saurabh Baheti; Sarah R Senum; Jennifer Arroyo; Charles D Madsen; Claude Férec; Dominique Joly; François Jouret; Oussamah Fikri-Benbrahim; Christophe Charasse; Jean-Marie Coulibaly; Alan S Yu; Korosh Khalili; York Pei; Stefan Somlo; Yannick Le Meur; Vicente E Torres; Peter C Harris Journal: Am J Hum Genet Date: 2018-04-26 Impact factor: 11.025
Authors: Li Chen; Xia Zhou; Lucy X Fan; Ying Yao; Katherine I Swenson-Fields; Mihaela Gadjeva; Darren P Wallace; Dorien J M Peters; Alan Yu; Jared J Grantham; Xiaogang Li Journal: J Clin Invest Date: 2015-05-11 Impact factor: 14.808
Authors: Andrew D Paterson; Riccardo Magistroni; Ning He; Kairong Wang; Ann Johnson; Pamela R Fain; Elizabeth Dicks; Patrick Parfrey; Peter St George-Hyslop; York Pei Journal: J Am Soc Nephrol Date: 2005-01-26 Impact factor: 10.121
Authors: Mark B Consugar; Wai C Wong; Patrick A Lundquist; Sandro Rossetti; Vickie J Kubly; Denise L Walker; Laureano J Rangel; Richard Aspinwall; W Patrick Niaudet; Seza Ozen; Albert David; Milen Velinov; Eric J Bergstralh; Kyongtae T Bae; Arlene B Chapman; Lisa M Guay-Woodford; Jared J Grantham; Vicente E Torres; Julian R Sampson; Brian D Dawson; Peter C Harris Journal: Kidney Int Date: 2008-09-24 Impact factor: 10.612
Authors: York Pei; Young-Hwan Hwang; John Conklin; Jamie L Sundsbak; Christina M Heyer; Winnie Chan; Kairong Wang; Ning He; Anand Rattansingh; Mostafa Atri; Peter C Harris; Masoom A Haider Journal: J Am Soc Nephrol Date: 2014-07-29 Impact factor: 10.121
Authors: Ronald D Perrone; Mohamad-Samer Mouksassi; Klaus Romero; Frank S Czerwiec; Arlene B Chapman; Berenice Y Gitomer; Vicente E Torres; Dana C Miskulin; Steve Broadbent; Jean F Marier Journal: Kidney Int Rep Date: 2017-01-16
Authors: Jonathan de Fallois; Ria Schönauer; Johannes Münch; Mato Nagel; Bernt Popp; Jan Halbritter Journal: Front Genet Date: 2021-06-25 Impact factor: 4.599